Welcome to our dedicated page for Incyte news (Ticker: INCY), a resource for investors and traders seeking the latest updates and insights on Incyte stock.
Incyte Corporation (INCY) reports developments for a biopharmaceutical business focused on hematology, oncology, and inflammation and autoimmunity. Recurring updates cover commercial medicines such as Jakafi, Jakafi XR, and Opzelura, regulatory decisions for approved and investigational therapies, and clinical data across blood cancers, graft-versus-host disease, dermatology, and solid tumors.
Company news also includes financial results, product revenue trends, pipeline progress, investor conference participation, executive appointments, equity inducement awards, and international regulatory updates tied to hematology and oncology therapies.
Incyte (Nasdaq: INCY) announced that more than 20 abstracts featuring its Hematology and Oncology portfolio have been accepted for presentation at the EHA 2026 Congress, held June 11–14, 2026 in Stockholm.
Highlights include pivotal Phase 3 frontMIND tafasitamab data in first-line DLBCL in a Plenary Session, and new clinical and preclinical results for INCA033989, INCA035784, INCB160058, axatilimab, ponatinib and ruxolitinib.
Incyte (Nasdaq:INCY) reported final Week 24 results from the Phase 3 TRuE-AD4 trial of Opzelura (ruxolitinib) cream in adults with moderate atopic dermatitis who had inadequate response, intolerance or contraindication to TCSs/TCIs. Patients continuing as-needed treatment through Week 24 showed 84.3% EASI75 and 70.6% IGA-TS. Mean affected BSA remained 2.5%; itch NRS4 response was 64.7% at Week 24. Safety showed few application-site reactions (1.7%) and no new signals; most common TEAEs were URTI (10.6%) and nasopharyngitis (6.3%). Data support a Type-II variation application in the EU; feedback expected 1H 2026.
Incyte (Nasdaq:INCY) granted inducement equity awards to Suketu Upadhyay upon his hire as Executive Vice President and Chief Financial Officer, effective May 4, 2026.
The inducement includes 38,429 stock options, 26,343 RSUs, and 13,171 target performance shares. Options have a $97.14 exercise price equal to the closing price on the grant date and a ten-year term. Options vest 25% at one year, then monthly over three years; RSUs vest 25% annually over four years. Performance shares vest after a three-year period and may pay 0–200% of target based on relative TSR vs. a fixed peer group, with the performance period beginning January 1, 2026.
Specialised Therapeutics / Incyte (NASDAQ: INCY) announced TGA approval of NIKTIMVO (axatilimab) for chronic graft-versus-host disease (cGVHD) in patients ≥6 years and ≥40 kg after ≥2 prior systemic therapies. Approval followed Priority Review; Australia is the first country granted marketing authorisation after the US FDA decision.
The TGA decision relied on the AGAVE-201 trial (n=241) showing a 74% overall response rate at the approved 0.3 mg/kg biweekly dose and 60% durability at 12 months.
Incyte (Nasdaq: INCY) announced FDA approval of Jakafi XR (ruxolitinib) extended-release tablets for adults with intermediate- or high-risk myelofibrosis, adults with polycythemia vera intolerant or unresponsive to hydroxyurea, and adults and children ≥12 years with steroid-refractory acute or chronic GVHD after 1–2 prior systemic therapies.
FDA approval was supported by bioequivalence showing a single 55 mg Jakafi XR tablet once-daily provides comparable steady-state exposure to 25 mg immediate-release Jakafi taken twice-daily. Jakafi XR will be available for pharmacy orders by May 8. Incyte offers patient support via IncyteCARES.
Incyte (Nasdaq: INCY) will present at two investor conferences in May 2026: BofA Securities 2026 Health Care Conference on May 13, 2026 at 1:40 pm PDT and RBC 2026 Global Healthcare Conference on May 19, 2026 at 10:30 am EDT.
Both presentations will be webcast live and can be accessed at Investor.Incyte.com; replays will be available for 30 days.
Incyte (Nasdaq:INCY) named Suketu (Suky) Upadhyay as Executive Vice President and Chief Financial Officer, effective May 4, 2026. He will lead global finance, capital allocation, investor relations, ESG, IT and facilities as a member of the Executive Leadership Team.
Mr. Upadhyay joins from Zimmer Biomet and previously held senior finance roles at Bristol Myers Squibb, Endo International, Becton Dickinson, AstraZeneca and Johnson & Johnson. He holds a BS in Finance and an MBA from Duke Fuqua.
Incyte (NASDAQ:INCY) reported Q1 2026 total revenue of $1.27B (+21% YoY) and total net sales of $1.10B (+20% YoY). GAAP net income was $303.3M with GAAP diluted EPS of $1.47. Cash and marketable securities totaled $4.0B as of March 31, 2026.
The company highlighted four anticipated approvals/launches from mid-2026 into early 2027, positive Phase 3 vitiligo results for povorcitinib, NDA acceptance in HS, and a late-stage pipeline with 10 ongoing Phase 3 studies, including a new Phase 3 in KRAS G12D PDAC.
Specialised Therapeutics announced TGA registration of Minjuvi (tafasitamab) in combination with rituximab and lenalidomide for adults with relapsed or refractory follicular lymphoma (Grade 1-3a) in Australia.
The approval makes Minjuvi the first chemotherapy-free CD19/CD20 dual-targeted immunotherapy regimen in Australia; Phase 3 inMIND (652 patients; 548 R/R FL) showed median PFS 22.4 months versus 13.9 months (57% risk reduction). PBS listing is not yet in place.
Incyte (Nasdaq:INCY) announced that full results from the Phase 3 frontMIND study of tafasitamab (Monjuvi/Minjuvi) in first-line diffuse large B-cell lymphoma (DLBCL) will be presented orally at the 2026 ASCO Annual Meeting.
The presentation is scheduled for May 30, 2026, 4:00–7:00 p.m. ET (Oral Abstract Session, Abstract #7000). According to the company, the results were positive and will support global regulatory submissions and further pipeline progress.